Targeting myeloid cells to improve cancer immune therapy
Tumor immunosuppression remains a major barrier to effective cancer immunotherapy and is often driven by the immunoregulatory activities of innate immune cells, such as myeloid cells within the tumor microenvironment (TME). Myeloid populations—including tumor-associated macrophages (TAMs), dendritic...
Saved in:
| Main Authors: | Hui Chen, Zihan Xu, Judith Varner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623436/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AXL in myeloid malignancies – an elusive target?
by: Pia Aehnlich, et al.
Published: (2024-12-01) -
CSF1R inhibitor (PLX3397) alleviates experimental periodontitis by reducing macrophage senescence through the PI3K/AKT/FOXO1 signaling pathway
by: Jiabing Kang, et al.
Published: (2025-07-01) -
Pexidartinib Inhibits Macrophage Senescence Through Glycolysis in Periodontitis Microenvironment
by: Jifan Zhan, et al.
Published: (2025-08-01) -
Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression
by: Iris Wyrobnik, et al.
Published: (2023-12-01) -
A rare intronic c.2654+1G>A mutation in CSF1R-microglial encephalopathy: a case report
by: HongYan Wu, et al.
Published: (2025-08-01)